College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Dophacyl SB 1000 mg/g, powder for use in drinking water/milk for cattle and pigs

PRODUCT SUMMARY

EU procedure number	NL/V/0392/001/DC
Name, strength and pharmaceutical form	Dophacyl SB 1000 mg/g, powder for use in drinking water/milk for cattle and pigs
Applicant	Dopharma Research B.V. Zalmweg 24 4941 VX Raamsdonksveer The Netherlands
Active substance(s)	Sodium salicylate
ATC vetcode	QN02BA04
Target species	Cattle and pigs.
Indication for use	Calves: For supportive treatment of pyrexia in acute respiratory disease, in combination with appropriate (e.g. anti-infective) therapy if necessary. Pigs: - for the treatment of inflammation, in combination with appropriate (e.g. anti-infective) therapy if necessary; - to promote recovery of respiration and to reduce coughing in respiratory infections, in combination with concurrent antibiotic therapy.

PRODUCT INFORMATION

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

SUMMARY OF ASSESSMENT

Legal basis of original application*	Generic application made in accordance with Article 18 of Regulation (EU) 2019/6
Reference product (RP)	Na-salicylaat 100%
Marketing authorisation holder	Dopharma Research B.V
MS where the RP is or has been authorised	NL
Marketing authorisation number EU procedure number	REG NL 8913
Date of authorisation	November 1998
Date of completion of the original decentralised procedure	28th of June 2023
Date veterinary medicinal product first authorised in the Reference Member State (MRP only)	-
Concerned Member States for original procedure	AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IT, LT, LV, LU, NO, PL, PT, RO, SE, SK
Concerned Member States for subsequent recognition procedure	-
Withdrawn CMS during original <mutual recognition> <decentralised><subsequent recognition> procedure	NA

*Please be aware that certain parts of the dossier may be varied and consequently be subject to protection of technical documentation – for these and other changes of referenceability to parts of the dossier, please see chapter POST-AUTHORISATION PROCEDURES

1. SCIENTIFIC OVERVIEW

The veterinary medicinal product (VMP) is produced and controlled using validated methods and tests, which ensure the consistency of the VMP released on the market.

It has been shown that the VMP can be safely used in the target species; the reactions observed are indicated in the SPC.

The VMP is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the VMP was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

2. QUALITY DOCUMENTATION

A. Product description

The product contains Sodium salicylate (1000 mg/g) as active substance, corresponding to 863 mg/g of salicylic acid. No excipients are used in the formulation of the drug product.

Two types of container closure systems are proposed: Bucket (3.2, 5.7 and 10.8 litres, which contain 1 kg, 2.5 kg and 5 kg of product, respectively), and Securitainer (1.3 and 1.9 litres, which contain 500 g and 1 kg of product, respectively).

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

A bioequivalence study has not been performed but it is not necessary as per section 7.1.c of the EMA Guideline on the conduct of bioequivalence studies for veterinary medicinal products.

In general, the applicant provides sufficient characterization of the most relevant physico-chemical properties of the drug substance. The solubility of the drug product in soft and hard water as well as in milk replacer has been demonstrated at two different temperatures as per requirements of the EMA Guideline on the Quality aspects of pharmaceutical veterinary medicines for administration via drinking water. No differences between pH and/or temperatures are observed.

B. Description of the manufacturing method

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site. No validation data are presented but this is not deemed required. The proposed commercial batch size range is acceptable.

C. Production and control of starting materials

The active substance is Sodium salicylate, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification of the DPM is considered adequate to control the quality of the API.

For the drug substance from manufacturer 1 the ASMF procedure has been used, and batch analytical data demonstrating compliance with this specification have been provided.

For the drug substance from manufacturer 2 full information has been provided. The proposed starting material is acceptable.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control tests carried out on isolated intermediates during the manufacturing process

Not applicable.

E. Control tests on the finished product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification at release.

F. Stability tests

Drug substance:

The retest period for Sodium salicylate from manufacturer 2 is 60 months when packed in LDPE bags inserted in paper laminated bags. The drug substance should be kept below 25°C and protected from light in view of the data.

The retest period for Sodium salicylate from manufacturer 1 is 36 months without temperature restriction if protected from light and packed in LDPE bags inserted in HDPE paper laminated bags.

For the Sodium salicylate from manufacturer 1 packed in Jumbo bag, stability studies have been provided for three production-scaled batches under accelerated and long-term stability conditions for six months. The results so far are within the proposed specification limits. The applicant commits to complete the stability testing of the batches packed in the Jumbo bag for 42 months and will provide the results as soon as they are available. No ret-test period can be approved. The applicant indicates that until the stability study is concluded, customer should test the material supplied in 500 kg Jumbo bag immediately before use.

Drug product:

Stability data on three batches of the finished product have been provided in accordance with applicable European guidelines. The proposed shelf life of three years can be granted for the drug product packed in both securitainer and bucket in view of the data presented and as per Decision Tree of the VICH GL51.

The proposed in-use shelf life after first opening of 3 months when stored in the original container is acceptable in view of the data provided acceptable.

The applicant has adequately tested the stability of the reconstituted product in water prepared as per requirements described in Appendix I to the EMA Guideline on Quality aspects of pharmaceutical veterinary medicines for administration via drinking water. In view of the

results, the proposed in-use shelf life of 24 hours is accepted for the reconstituted product in water.

The proposed in-use shelf life of 6 hours for the reconstituted product in milk (replacer) is accepted in view of the data presented.

G. Other information

Not applicable.

3. SAFETY DOCUMENTATION (safety and residues tests)

As this is an application submitted in accordance with article 18 of Regulation (EU) 2019/6, a so called generic application and if bioequivalence with the reference product has been established, results of toxicological, pharmacological or clinical tests are not required.

The safety aspects of this VMP are identical to the reference VMP.

Warnings and precautions as listed on the product literature are the same as those of the reference VMP and supplemented with additional statements, based on increased knowledge and the current state of science. This information is considered adequate to ensure safety of the product to users, consumers and the environment

User safety

The applicant has provided a user safety assessment in compliance with the relevant guideline. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the VMP.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines. The assessment concluded that no impairment of the environment will occur as a consequence of the use of this VMP in calves and pigs and no further assessment is required

No warnings regarding the environment are therefore required.

4. EFFICACY DOCUMENTATION (preclinical studies and clinical trials)

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, efficacy studies are not required. The efficacy claims for this VMP are equivalent to those of the reference VMP.

5. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the VMP is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the VMP for humans and the environment is acceptable.

POST-AUTHORISATION PROCEDURES

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the VMP. The current SPC is available in the Union Product Database (UPD).

This section contains information on significant changes, which have been made after the original procedure, which are important for the quality, safety or efficacy of the VMP.

None